PSYCHOTHERAPY FOR ADOLESCENTS, CHildren AND ADULTS
CYB003 is a next-generation psilocybin designed to provide a faster onset of action and to reduce the duration of effects, ultimately thinning the financial barrier to access of this medicine in a medical setting.
The trial’s interim data demonstrated “rapid, robust, and clinically significant reduction of depression symptoms” three weeks after a single 12mg dose of CYB003.
Read moreIn the 1960s, psychedelic research was driven underground. Now it’s re-emerging – with lessons for the study of psychosis.
Read moreAuthor Julien Bonhomme, Ph.D explores how Euro-American psychedelic communities have appropriated Bwiti ibogaine rituals, creating a liminal experience that incorporates from both traditions.
Click here for the full article.
Read moreFrom the article on indigenous cultures and relationships with the plants: A lot of people today are tripping balls once a week, because they aren’t in right relation and are stuck in an ecstatic loop of entropy. They have no tether to a place, no kin, and no purpose for the work, so no work is delegated to them.
Read moreThis podcast discusses how psychedelics reopen critical periods of learning, and how the true benefit of psychedelics could be in learning how best to reopen those critical periods, how long they’re open for, and which therapeutic frameworks and integration practices could best take advantage of them.
Read morehow the nature of capitalism and returning profits to shareholders affects the concept of set and setting; how easy it is to prescribe ketamine and the puppy mill clinics popping up everywhere; how innovators are racing to the bottom to get ahead; the designer drug epidemic likely leading us to a Prozac Nation 2.0; digital narcissism, Instagram “Shamans,” and the dangers of cults; chemists trying to take the experience out of the drug; the overuse of psychedelics creating super egos; and much more.
Read moreKeep reading for five questions with ethnopharmacologist Matteo Politi.
Read moreThe most common forms of extended difficulty were feelings of anxiety and fear, existential struggle, social disconnection, depersonalization and derealization.
For approximately one-third of the participants, problems persisted for over a year, and for a sixth, they endured for more than three years.
It was found that a shorter duration of difficulties was predicted by knowledge of dose, drug type and lower levels of difficulty reported during the psychoactive experience, while a narrower range of difficulties was predicted by taking the drug in a guided setting.
Read moreA new study suggests that dosage, age, and neuroticism may predict the intensity of a psychedelic experience, whether mystical (positive) or challenging.
Read moreThe criminalization of drug production and consumption is driving widespread environmental damage and impeding efforts to stop climate change, a new report from The International Coalition on Drug Policy Reform & Environmental Justice warned today, in advance of the International Drug Policy Reform Conference and less than two months before the UN Climate Change Conference in Dubai.
The report unveils how prohibitive drug policies – which drive drug cultivation into remote and incredibly fragile ecosystems to evade law enforcement detection – are undermining environmental progress and governance in the world’s tropical forest frontiers.
Read more